AuBEX Corp. engages in the manufacture and sale of writing materials and medical products. It operates through the following segments: Techno Products, Medical Products, and Others. The Techno Products segment manufactures and sells sign pens and cosmetics. The Medical Products segment handles the manufacture and sale of medical equipment. The Others segment engages in the lease and sale of real estate properties. The company was founded by Eiichi Shibusawa on December 12, 1892 and is headquartered in Tokyo, Japan.

The Lee Co. supplies precision fluid control products to industries including aerospace, formula 1 racing, oil exploration, automotive and off-highway equipment, and medical and scientific instruments. Its products include precision microhydraulics and electro-fluidic systems. The company was founded by Leighton Lee II in 1948 and is headquartered in Westbrook, CT.

Isofol Medical AB (publ.) is a biotech company working with the development of the cancer drug, arfolitixorin. Arfolitixorin is a new drug candidate that Isofol is primarily developing to treat colorectal cancer (CRC) – the third most common type of cancer and one for which there is a substantial need for more effective drugs. Isofol’s development work with arfolitixorin is also targeting so-called “rescue therapy” after high-dose chemotherapy with methotrexate in conjunction with osteosarcoma (bone cancer). Other potential uses for arfolitixorin also includes the treatment of pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. When treating colorectal cancer, arfolitixorin is administered in combination with the cytotoxic agent, 5-FU (5-fluorouracil), in order to improve tumour size reduction and extend the life of the cancer patient. The active substance in arfolitixorin is MTHF ([6R]-5, 10-methylenetetrahydrofolate). The folate-based prodrugs, leucovorin and levoleucovorin, are currently used in combination with the cytotoxic agent, 5-FU, in the treatment of colorectal cancer. Isofol intends to replace leucovorin and levoleucovorin with arfolitixorin, with the primary aim of improving the treatment for over 365,000 colorectal cancer patients in the USA, Europe and Japan. Unlike leucovorin and levoleucovorin, which must be metabolised into MTHF in the body in order to be effective in the treatment of cancer, arfolitixorin’s active substance is MTHF, which means that no metabolic activation is required and arfolitixorin consequently has the potential to achieve a more powerful antitumoural effect for all patients in combination with 5-FU treatment. Thanks to a global licensing agreement with Merck KGaA, Germany, Isofol has gained the exclusive right to develop and commercialise arfolitixorin in the field of oncology. The licensing agreement with Merck also gives Isofol access to the unique, patented MTHF/arfolitixorin manufacturing process. Isofol’s operations are based in Gothenburg and the company’s share is traded on the NASDAQ First North Premier exchange.

Insulet Corporation, a medical device company, engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes primarily in the United States. The company offers OmniPod Insulin Management System (OmniPod System), an insulin infusion system that provides a pain-free automated cannula insertion. The OmniPod System consists of OmniPod disposable insulin infusion device and handheld wireless personal diabetes manager; and provides people with a diabetes management solution that offers lifestyle and other benefits. The company sells the OmniPod System directly to patients through referrals from healthcare professionals and through patient leads. Insulet Corporation was founded in 2000 and is headquartered in Bedford, Massachusetts.

ALZA Corp. is a pharmaceutical and medical systems company that develops, manufactures, and markets therapeutic systems. It provides oral, transdermal, implantable, and liposomal technologies. It is also focused on drug delivery systems with over 20 prescription pharmaceutical products. With over 10,000 employees, ALZA Corp. is a subsidiary of Johnson & Johnson. It was established in 1968 by Dr Alejandro Zaffaroni. It is based inVacaville, California.

Manufactures pharmaceuticals

Trudell Medical International designs, develops and manufactures aerosol drug delivery devices for human and animal health applications. It serves to the pharmaceutical and health care industries. The company was founded in 1922 and is headquartered in London, Canada.

LifeScan manufactures and markets blood glucose monitoring systems. The company’s product portfolio includes blood glucose meters, test strips, lancing devices, and diabetes management software solutions, hospital meters, data management systems, glucose control solutions, and linearity test kits. Additionally, the company provides pre-installation project management, installation, and post installation support services, including on-site and on-line training programs through authorized distributors such as doctors, pharmacists, and diabetes educators. Lifescan was founded in 1981 and is headquartered in Milpitas, California.  The company currently operates as a subsidiary of Johnson & Johnson and has facilities in Inverness, Scotland; Burnaby, British Columbia, Canada; and Cabo Rojo, Puerto Rico.

Bigfoot Biomedical is a medical device company changing diabetes care for people with insulin-requiring diabetes. The company developing an end-to-end type 1 diabetes management system using a simple design, cloud connectivity, and human-centered automation. It optimizes the dosing and delivery of insulin through an integrated medical device ecosystem powered by machine learning and enhanced by secure, user-friendly consumer technologies, fundamentally changing the paradigm of care. Biofoot Biomedical ’s pioneering smartphone-enabled systems include both automated infusion pump and connected insulin pen options for consumers and will be delivered via a first-of-its-kind monthly subscription service model. By employing data-driven intelligence across an integrated device ecosystem, they are transforming diabetes care with a fully comprehensive digital drug delivery platform experienced as a service.

Engages in owning and leasing franchise, patents and copyrights

MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Westlake Village, California, the company was founded in February 1991. However, its present form is a result of a 2003 merger of three companies owned by Alfred E. Mann, Pharmaceutical Discovery Corporation (PDC), the cancer vaccine developer CTL ImmunoTherapies, Inc., and its sister company Allecure Corp, which was developing a allergy vaccine technology. MannKind Corporation was named after its founder, Alfred Mann. One of the former companies, Pharmaceutical Discovery, was purchased in 2001 from Solomon Steiner; with that purchase MannKind acquired the Technosphere molecule and Medtone inhaler, upon which was developed its lead product, Afrezza (inhalable insulin).

Henan Xiuhe Pharmaceutical Technology Co., Ltd., established on 2020-07-13, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Chinese herbal medicine planting;market survey(Does not include foreign investigations);Health Consulting Services(Does not include medical services);Business Management Consulting;marketing planning;Organize cultural and artistic exchange activities;Sales of bio-based materials;Healthy food(prepackaged)Sales;Sales of Class I Medical Devices;Instrument sales;General merchandise sales;Sales of agricultural and sideline products;food sales(Only sell prepackaged food);Sales of Class II Medical Devices;Medical Mask Retail;Retailing of protective equipment for healthcare workers;daily mask(non-medical)Sales;Sporting Goods and Equipment Retailing;internet sales(Except for products that require a license for sale);Traditional spice products business;Chinese herbal medicine acquisition;Sale of spray guns and similar appliances;Sales of special equipment for agricultural and sideline food processing;wooden container sale;Brown products sales;Bamboo Products Sales;Pharmaceutical special equipment sales;Food Internet Sales(Only sell prepackaged food);Import and export;Technology Import and Export(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:food sales;Drug retail;Food Internet Sales;medical service;Chinese Herbal Pieces Decoction Service;Information network dissemination of audio-visual programs(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, training and youth pants, swim pants, baby wipes, feminine and incontinence care products, and other related products. The Consumer Tissue segment produces and sells facial and bathroom tissue, paper towels, napkins, and related products for household use. The K-C Professional segment supplies workplace supporting products such as wipers, tissue, towels, apparel, soaps, and sanitizers. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Taiyuan Daningtang Pharmaceutical Co., Ltd., established on 1999-04-20, Business range includes tablet,hard capsule,soft capsule,Granules,Powder,pill(honey pill,water pill,honey pill,Concentrated pills),production of liquor;health food tablet,Production of soft capsules(Operate for the validity period of the license);Catering Services;Acquisition and processing of Chinese herbal medicines;Production of Medical Devices;Medical device management:Sales of Medical Devices;Import and export;Technology Import and Export;food production;food business:Production and sales of prepackaged food.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Jiangxi Yiyuansheng Nutritional Products Co., Ltd., established on 2020-06-10, Business scope includes licensed projects:beverage production,food production,Health food production,food business(sell bulk food),food business(Selling prepackaged food),dairy production,Production of tea products,Production of formula food for special medical purpose,Food Internet Sales(Selling prepackaged food),Production of protective equipment for medical personnel(Class II medical device),Production of Class II Medical Devices,Class III medical device business,Production of Class III Medical Devices,Production of medical masks,Disinfectant production(Free of Hazardous Chemicals),Production of sterile equipment,Technology Import and Export,Import and export agency,pharmaceutical production,Pharmaceutical commissioned production,Food additive production(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Sales of Class II Medical Devices,Production of protective equipment for medical personnel(Ι class medical device),Production of Class I Medical Devices,Sales of Class I Medical Devices,Domestic trade agent,Information Technology Consulting Services,Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,Information Consulting Service(Not including licensing information consulting services),Socioeconomic Advisory Services,Manufacturing of bio-based materials,Extraction of marine bioactive substances,purification,Synthesis technology research and development,R&D of industrial enzyme preparations(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

Zhejiang University of Traditional Chinese Medicine Co., Ltd., established on 1989-11-07, Business scope includes pharmaceutical production;Planting of Chinese herbal medicines(Seedling removal);Acquisition of Chinese herbal medicines(In addition to national special regulations);Sales of agricultural and sideline products(In addition to national special regulations);Research and development of Chinese patent medicine preparations;Traditional Chinese Medicine.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.